Blood THC Metabolite Levels — Not Self-Report — Predicted Depression Symptoms in Young Cannabis Users

Among 94 young adults, only plasma THCCOOH concentration (not self-reported use or other biological samples) uniquely predicted depression symptoms, suggesting blood-based cannabinoid testing may reveal clinical risks that self-report misses.

Wade, Natasha E et al.·Journal of analytical toxicology·2025·Moderate EvidenceCross-Sectional
RTHC-07891Cross SectionalModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Plasma THCCOOH concentration uniquely predicted depression symptoms (beta = 4.43, p < 0.001), while self-reported use days, oral fluid, urine, and hair concentrations did not. All toxicological matrices except oral fluid showed adequate sensitivity (63–74%) for detecting cannabis use, and concentrations did not differ by route of administration.

Key Numbers

70 cannabis users, 24 non-users. Ages 18–21, 64% female. Oral fluid sensitivity only 12% (vs 63–74% other matrices). Self-report and toxicological metrics correlated (r = 0.41–0.97). Plasma THCCOOH predicted depression (β = 4.43, p < 0.001). No difference by route of administration.

How They Did This

Cross-sectional study of 70 cannabis-using and 24 non-using young adults (ages 18–21, 64% female). Oral fluid, plasma, urine, and hair tested for THCCOOH. Self-reported use, route of administration (smoked flower vs. vaped concentrate), and depression symptoms assessed. ANOVAs and regression models examined relationships.

Why This Research Matters

This finding suggests that objective blood measurements capture something about cannabis exposure that self-report cannot — potentially reflecting cumulative body burden or metabolic differences that are directly relevant to mental health outcomes.

The Bigger Picture

If plasma cannabinoid levels predict clinical outcomes better than self-report, clinical practice might benefit from incorporating biological testing when assessing cannabis-related mental health risks, especially in young adults.

What This Study Doesn't Tell Us

Cross-sectional — depression could cause heavier use rather than the reverse. Small sample. Oral fluid had very poor sensitivity (12%). Cannot determine if plasma levels reflect recent heavy use or slower metabolism. Depression measured by self-report.

Questions This Raises

  • ?Why did only plasma THCCOOH predict depression?
  • ?Does plasma level reflect cumulative exposure, metabolic differences, or recent dose?
  • ?Would longitudinal studies confirm this biomarker-outcome relationship?

Trust & Context

Key Stat:
Evidence Grade:
Multi-matrix toxicological assessment with clinical correlation, but cross-sectional design and small sample limit causal conclusions.
Study Age:
Published 2025.
Original Title:
Cannabinoid profiling across toxicology samples in adolescents and young adults by route of administration and in relation to depression symptoms.
Published In:
Journal of analytical toxicology, 49(8), 567-575 (2025)
Database ID:
RTHC-07891

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

Does smoking vs. vaping cannabis matter for health effects?

In this study, THCCOOH concentrations did not differ between people who smoked flower versus vaped concentrates, and self-reported use patterns were also similar. Route of administration didn't affect the depression relationship.

Why was oral fluid testing so poor at detecting cannabis?

Oral fluid had only 12% sensitivity, meaning it missed most cannabis users. This may be because oral fluid THC levels drop quickly after use and depend heavily on time since last use, making it unreliable for detecting regular users.

Read More on RethinkTHC

Cite This Study

RTHC-07891·https://rethinkthc.com/research/RTHC-07891

APA

Wade, Natasha E; Wallace, Alexander L; Baca, Rachel; Andrade, Gianna; Happer, Joseph P; Courtney, Kelly E; Christians, Uwe; Sempio, Cristina; Klawitter, Jost; Huestis, Marilyn A; Jacobus, Joanna. (2025). Cannabinoid profiling across toxicology samples in adolescents and young adults by route of administration and in relation to depression symptoms.. Journal of analytical toxicology, 49(8), 567-575. https://doi.org/10.1093/jat/bkaf051

MLA

Wade, Natasha E, et al. "Cannabinoid profiling across toxicology samples in adolescents and young adults by route of administration and in relation to depression symptoms.." Journal of analytical toxicology, 2025. https://doi.org/10.1093/jat/bkaf051

RethinkTHC

RethinkTHC Research Database. "Cannabinoid profiling across toxicology samples in adolescen..." RTHC-07891. Retrieved from https://rethinkthc.com/research/wade-2025-cannabinoid-profiling-across-toxicology

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.